The $500 Million Non-CF Factor Vertex Investors Can’t Ignore on Nov. 2

Vertex Pharmaceuticals (NASDAQ:VRTX) reports third-quarter results on Nov. 2. Cystic fibrosis still pays the bills, but I’ll be watching whether CASGEVY and JOURNAVX stay on pace for management’s $500 million non-CF revenue target. Diversification Picks Up Speed After a Raised Outlook Second-quarter revenue rose 12.4% to $3.33 billion, exceeding the $3.22 billion consensus. Adjusted EPS […]